A prospective, randomized, double dummy, double blind, multi-center trial comparing the safety and efficacy of moxifloxacin 400 mg IV QD 24 hours to that of ertapenem 1.0 g IV QD 24 hours for 5 to 14 days for the treatment of subjects with complicated intra-abdominal infections (PROMISE Study).

Trial Profile

A prospective, randomized, double dummy, double blind, multi-center trial comparing the safety and efficacy of moxifloxacin 400 mg IV QD 24 hours to that of ertapenem 1.0 g IV QD 24 hours for 5 to 14 days for the treatment of subjects with complicated intra-abdominal infections (PROMISE Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs Moxifloxacin (Primary) ; Ertapenem
  • Indications Bacteroides infections; Escherichia coli infections; Intra-abdominal infections; Streptococcal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PROMISE
  • Sponsors Bayer
  • Most Recent Events

    • 02 Aug 2011 New source identifed and integrated (European Clinical Trials Database).
    • 13 Sep 2010 Primary endpoint results (n=573) presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • 13 Apr 2010 Primary endpoint 'Clinical-cure-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top